Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study
一项针对不适合接受经导管动脉化疗栓塞术(TACE)且肿瘤负荷超过“Up-To-7”标准的中晚期肝细胞癌患者的阿特珠单抗联合贝伐珠单抗治疗的II期研究的主要分析:REPLACEMENT研究
期刊:Liver Cancer
影响因子:9.1
doi:10.1159/000546899
Kudo, Masatoshi; Ueshima, Kazuomi; Tsuchiya, Kaoru; Yamashita, Tatsuya; Shimose, Shigeo; Numata, Kazushi; Kodama, Yuzo; Itoh, Shinji; Tanaka, Yasuhito; Kuroda, Hidekatsu; Aikata, Hiroshi; Hiraoka, Atsushi; Moriguchi, Michihisa; Tateishi, Ryosuke; Ogasawara, Sadahisa; Yamamoto, Kouji; Ikeda, Masafumi